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206 Clinical and paraclinical proﬁle and risk of exacerbations in
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in Latin America
M.A. Rey1, G. Rutz1, G. Parallada1, M. Rios1, M. Castro1, D. Consentino1,
P. Ramirez1, M.N. Fontan1. 1Unidad de Fibrosis Quı´stica del BPS, Montevideo,
Uruguay
Cystic ﬁbrosis (CF) is characterized by chronic airway and systemic inﬂammation
complicated by intermittent episodes of acute exacerbations that contribute to
signiﬁcant morbidity.
Objectives: To characterize and identify possible risk factors related to exacerba-
tions in CF patients attending the National Reference Center in Uruguay.
Methods: We analyzed data from all patients at the database of our center for
the period 2011–2012. One patient who died and two patients, who underwent
double lung transplantation, were excluded. Exacerbations were deﬁned as acute/
sub-acute worsening of respiratory symptoms severe enough to warrant intravenous
(IV) antibiotics and hospitalization.
Results: 54 patients were included, 57.4% male, mean age 26±9, BMI 22±4.
At least one of the most common mutation delta F508, was present in 35%,
pancreatic insufﬁciency in 44%, diabetes in 9% and hemoptysis in 62%. Up to 70%
were colonized with: Pseudomonas aeruginosa (PA) 52%, St. aureus 26.3%,
Alcaligenes 13%, Stenotrophomonas 2.6%. Mean FVC 90.1±23%, mean FEV1
80.6±27.8; 18.5% FEV1 <60%. Patients received treatment with: inhaled to-
bramycin 44%, pulmozyme 51.8%, Hypertonic Saline solution 61%. 35% of
patients had at least one exacerbation or hospitalization/year. Using a linear
regression model no correlation was found between exacerbations and: sex, age,
age at diagnosis, colonization with PA, or hemoptysis. Exacerbations were strongly
associated with poor lung function (R: 0.51, p = 0.0001).
Conclusions: Data from a well characterized CF population suggest that ac-
knowledging trends in lung function may contribute to identify patients at risk
of exacerbation and increased morbidity.
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Objectives: The primary cause of death in cystic ﬁbrosis (CF) is respiratory failure
(RF). In advanced CF, non-invasive ventilation (NIV) plays an important role as a
bridge to lung transplant. We aim to study other potential beneﬁts of NIV.
Methods: Retrospective study of children with CF under NIV at Lisbon CF Centre.
Collected data: previous clinical status, duration of NIV and outcome.
Results: Among a total of 210 children followed, 12 have initiated NIV (the 1st in
1995), with a mean age of 16.7 years (±3.9 y). All were previously O2 dependent
and NIV was started due to global RF and associated increased work of breathing.
The initial ventilation parameters (median values) were 12 cmH2O (IPAP), 4 cmH2O
(EPAP) and 15 CPM (respiratory rate), and all patients needed upregulation of the
parameters.
Two patients remain on NIV for 3.6 and 6 months (mo) each. Four patients were
successfully transplanted, but one died few months after from sepsis. The other
patients died without being transplanted because they were on the waiting list,
did not fulﬁll transplant criteria or their death preceded the start of the transplant
program in Portugal. At the beginning of NIV the 5 patients who are alive presented
median values of FEV1 and FEF25−75 of 34.5% (32.1−48%) and 12.3% (7.4−17%),
respectively. Four showed a BMI percentile <5th. The patients who died had a
median period of 9.6m (2.4–63.6m) on NIV. The median duration of NIV was
18mo (12−56mo) among the 3 alive successfully transplanted children. During
NIV patients showed improvements concerning quality of life (reduced respiratory
effort and sleep quality gain).
Conclusion: Our experience suggests that NIV is an important management tool
for patients with severe CF and it can improve QOL.
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Introduction: Flexible bronchoscopy is increasingly used in children with cystic
ﬁbrosis (CF) for therapeutic and diagnostic reasons. It is a safe procedure and
bronchoalveolar lavage (BAL) culture enables deﬁnitive microbiological diagnoses
in those patients who are unable or unwilling to expectorate sputum. In this study
we aimed to review our bronchoscopy practice in patients with cystic ﬁbrosis, and
evaluate subsequent management changes.
Methods: We conducted a retrospective case note review of all ﬂexible bron-
choscopies carried out on paediatric patients with CF between May 2009 and
September 2012.
Results: We performed 64 bronchoscopies on 36 patients with CF (median age
6.0 years, IQR 4.0–11.0). The main indication for bronchoscopy was the need for a
microbiological diagnosis. We obtained positive BAL cultures in 54 bronchoscopies
isolating a total of 111 organisms. Organisms were grown for the ﬁrst time in 22
bronchoscopies including Pseudomonas aeruginosa in 2 patients and Aspergillus
fumigatus in 9 patients. A further 30 bronchoscopies grew organisms not isolated
from routine culture in the last year. The bronchoscopy ﬁndings lead to a treatment
being changed or modiﬁed on 36/64 occasions. Most commonly this was a change
in antibiotic regimen, the targeting of physiotherapy or the addition of a mucolytic
agent.
Conclusions: Flexible bronchoscopies with bronchoalveolar lavage are an important
tool in the management of children with CF. It allows detection of organisms
not isolated by conventional measures, including Pseudomonas aeruginosa and
provides a catalyst for management change in a signiﬁcant proportion of patients.
